Issue 98, 2019

A cyotosol-selective nitric oxide bomb as a new paradigm of an anticancer drug

Abstract

We have reported rational design of a polymeric NO delivery micelle as a cytosol-selective NO bomb. Protected NO-donors are released from the micelle under endolysosomal conditions, and then deprotected by cytosolic glutathione. Cytosol-selective NO delivery facilitates significant tumor regression without the aid of other therapeutic modalities even in intravenous administrations.

Graphical abstract: A cyotosol-selective nitric oxide bomb as a new paradigm of an anticancer drug

Supplementary files

Article information

Article type
Communication
Submitted
13 Oct 2019
Accepted
14 Nov 2019
First published
14 Nov 2019

Chem. Commun., 2019,55, 14789-14792

A cyotosol-selective nitric oxide bomb as a new paradigm of an anticancer drug

D. Park, S. Im, G. Saravanakumar, Y. M. Lee, J. Kim, K. Kim, J. Lee, J. Kim and W. J. Kim, Chem. Commun., 2019, 55, 14789 DOI: 10.1039/C9CC08028G

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements